InsiderTrades.com logo
Why I'm telling friends to avoid gold stocks
From DTI   |   Ad
Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."
And if you’d like to get your hands on this, here you go, the complete breakdown.
Fred B. Craves net worth and biography
  • Phone
  • Email
  • Website

Fred Craves Biography and Net Worth

Director of Madrigal Pharmaceuticals
Fred Craves, Ph.D. has served on Madrigal’s Board of Directors since July 2016. Dr. Craves co-founded and served as Chairman of the Board of Private Madrigal, a privately-held biopharmaceutical company, from its inception in September 2011 through the Merger involving Synta, in July of 2016. Dr. Craves is a Managing Director and co-founder of Bay City Capital. In the course of his career, Dr. Craves has founded and managed several biotechnology companies. Dr. Craves previously served on the boards of directors of several privately-held and publicly-held companies. Dr. Craves currently serves as a member of the board of directors of Synchronicity Pharma, Inc. and IMIDomics, Inc., each a privately-held life science company. During the past five years, Dr. Craves served as a member of the board of directors of Dermira, Inc., KBP Pharmaceuticals, Inc. and Twist Bioscience, Inc., each a publicly-held life science company. Dr. Craves earned a B.S. degree in biology from Georgetown University, an M.S. in biochemical pharmacology from Wayne State University and a Ph.D. in pharmacology and experimental toxicology from the University of California, San Francisco.

What is Fred B. Craves' net worth?

The estimated net worth of Fred B. Craves is at least $3.45 million as of December 3rd, 2024. Dr. Craves owns 11,000 shares of Madrigal Pharmaceuticals stock worth more than $3,454,440 as of December 26th. This net worth approximation does not reflect any other assets that Dr. Craves may own. Learn More about Fred B. Craves' net worth.

How do I contact Fred B. Craves?

The corporate mailing address for Dr. Craves and other Madrigal Pharmaceuticals executives is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. Madrigal Pharmaceuticals can also be reached via phone at (267) 824-2827 and via email at [email protected]. Learn More on Fred B. Craves' contact information.

Has Fred B. Craves been buying or selling shares of Madrigal Pharmaceuticals?

During the past quarter, Fred B. Craves has sold $2,326,136.00 in Madrigal Pharmaceuticals stock. Most recently, Fred B. Craves sold 3,600 shares of the business's stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $315.31, for a transaction totalling $1,135,116.00. Following the completion of the sale, the director now directly owns 11,000 shares of the company's stock, valued at $3,468,410. Learn More on Fred B. Craves' trading history.

Who are Madrigal Pharmaceuticals' active insiders?

Madrigal Pharmaceuticals' insider roster includes Fred Craves (Director), James Daly (Director), Paul Friedman (Director), Richard Levy (Director), Brian Lynch (SVP), William Sibold (CEO), Remy Sukhija (Sr. VP & Chief Commercial Officer), Rebecca Taub (Director, Founder, Chief Medical Officer and President of Research & Development), and Robert Waltermire (VP). Learn More on Madrigal Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Madrigal Pharmaceuticals?

During the last twelve months, insiders at the biopharmaceutical company sold shares 15 times. They sold a total of 192,284 shares worth more than $42,873,872.98. The most recent insider tranaction occured on December, 3rd when Director Fred B Craves sold 3,600 shares worth more than $1,135,116.00. Insiders at Madrigal Pharmaceuticals own 22.8% of the company. Learn More about insider trades at Madrigal Pharmaceuticals.

Information on this page was last updated on 12/3/2024.

Fred B. Craves Insider Trading History at Madrigal Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/3/2024Sell3,600$315.31$1,135,116.0011,000View SEC Filing Icon  
11/25/2024Sell3,400$350.30$1,191,020.0014,600View SEC Filing Icon  
5/14/2024Sell22,489$212.88$4,787,458.32413,362View SEC Filing Icon  
8/19/2020Sell30,000$109.74$3,292,200.00281,683View SEC Filing Icon  
11/19/2018Buy2,000$124.69$249,380.00View SEC Filing Icon  
See Full Table

Fred B. Craves Buying and Selling Activity at Madrigal Pharmaceuticals

This chart shows Fred B Craves's buying and selling at Madrigal Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Madrigal Pharmaceuticals Company Overview

Madrigal Pharmaceuticals logo
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $314.04
Low: $308.63
High: $314.64

50 Day Range

MA: $296.96
Low: $202.48
High: $354.85

2 Week Range

Now: $314.04
Low: $168.25
High: $368.29

Volume

136,329 shs

Average Volume

433,204 shs

Market Capitalization

$6.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Why I'm telling friends to avoid gold stocks
From DTI   |   Ad
Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."
And if you’d like to get your hands on this, here you go, the complete breakdown.